Solegear Launches good natured(TM) Sustainable Office Products at London Drugs Across Western Canada

Leading bioplastics innovator teams up with Canadian retailer to offer customers more eco-friendly choices


VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 6, 2016) - Solegear Bioplastic Technologies Inc. (TSX VENTURE:SGB) ("Solegear" or the "Company") is pleased to announce that its newly branded plant-based office organizer line good natured™ is now available in select London Drugs stores across Western Canada with the full suite of office organization products available online at www.londondrugs.com.

Working alongside London Drugs to meet growing demand from its customers for more eco-friendly options, this launch reinforces Solegear's initiatives to work collaboratively with industry leaders to seek out home and office organization products that are primed for revitalization using the Company's proprietary bioplastics.

"We're thrilled that London Drugs shares our same commitment to offering more unique and innovative products to its customer that are also better for the planet. These office organizers are just the start of where we see the good natured product portfolio developing over time," said Paul Antoniadis, CEO of Solegear. "With London Drugs input, we will continue our commitment to seek out home and office organization products that are ripe for a bioplastic make-over and re-introduce them under the good natured brand at prices that are comparable to traditional fossil-fuel based products."

"At London Drugs we are continuously looking to increase the number of eco-minded products in our stores," said Clifford Fong, Buyer, General Merchandise, London Drugs. "We are pleased to have Solegear's good natured ™ office organization products available for our customers who are particularly looking for products created from renewable plant-based sources. Over the past few years we have seen tremendous growth in customer interest in these types of products."

Manufactured in Canada from Solegear's independently certified 85% plant-based Polysole® LV1250 bioplastic, the good natured™ brand and suite of products are specifically targeting the growing multi-billion dollar home and business organization market that is primarily dominated by traditional, fossil fuel-based plastics that have been reported to contain materials and additives that may be harmful to the environment and human health.

About Solegear Bioplastic Technologies Inc.

Solegear Bioplastic Technologies Inc. (TSX VENTURE:SGB) is an innovator in the field of next generation bioplastics made from annually renewable plant-based sources. Committed to the principles of Green Chemistry, Solegear is driven by its mission to create healthier, safer and stronger communities by fundamentally changing the way plastics are made.

Solegear's proprietary bioplastic formulations, Polysole® and Traverse®, are designed to meet today's social and corporate requirements to lower carbon emissions, reduce waste and remove toxicity typically associated with traditional petroleum-based plastics. Together with its partners, Solegear custom engineers, produces and distributes its high-performance bioplastics as resin, sheets and finished goods with some of the highest percentages of renewable, plant-based materials currently available in the industry.

For more information: www.solegear.ca and www.mygoodnatured.com

About London Drugs

Founded in 1945, B.C.-based London Drugs has 79 stores in more than 35 major markets throughout British Columbia, Alberta, Saskatchewan and Manitoba including its online store www.londondrugs.com. London Drugs offers consumers a range of products from digital cameras and cosmetics to computers and televisions. Renowned for its creative approach to retailing, the company employs more than 7,500 people with pharmacy and health care services being the heart of its business. Committed to innovation and superior customer service, London Drugs has established itself as a reputable and caring company and continues to position itself for future growth and development. @LondonDrugs

On behalf of the Company:

"Paul Antoniadis" Chief Executive Officer and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibilities for the adequacy or accuracy of this release.

This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

Cautionary Statement Regarding Forward-Looking Information

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the risk that: (i) future orders may not be placed by the customer; and (ii) that sales projections may not be within the current range forecasted.

When relying on the Company's forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Other than as required under securities laws, we do not undertake to update this information at any particular time.

Forward-looking information contained in this news release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. The reader should not place undue importance on forward-looking information and should not rely upon this information as of any other date. All forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement.

Contact Information:

Solegear Bioplastic Technologies Inc.
Paul Antoniadis
Chief Executive Officer and Director
604-998-4058
www.solegear.ca
www.mygoodnatured.com

Investor Contact:
Caleb Jeffries
Kin Communications
1-866-684-6730
SGB@kincommunications.com

Media Contact:
Elisha McCallum
FleishmanHillard Vancouver
778-668-0185
Elisha.McCallum@fleishman.ca